Abstract 146P
Background
The CROSS and NEOCRTEC-5010 trials established neoadjuvant chemoradiotherapy (nCRT) as the standard for locally advanced esophageal cancer (EC). The ESCORT-NEO study showed the efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in locally advanced esophageal squamous cell carcinoma (LA-ESCC). However, reports on the combined approach in adenocarcinoma of the esophagogastric junction (AEG) are lacking. This phase II trial evaluates the efficacy and safety of neoadjuvant adebrelimab with nab-paclitaxel, lobaplatin, and S-1 in resectable locally advanced AEG.
Methods
Treatment-naive patients with cT3-4NanyM0 resectable locally advanced AEG and ECOG PS 0-1 received adebrelimab (1200 mg IV) on Day 1, nab-paclitaxel (180-200 mg IV) on Day 1, lobaplatin (50 mg IV 2h) on Day 1, and S-1 (40 mg, bid po) every 3 weeks for 2 cycles, followed by surgery and investigator's choice of adjuvant treatment. The primary endpoint was the pathologic complete response (pCR) rate; secondary endpoints included R0 resection rate, overall response rate (ORR), event-free survival (EFS), disease-free survival (DFS), safety.
Results
From November 2023 to June 2024, 15 patients were enrolled and completed neoadjuvant treatment; 2 patients were lost to follow-up, and 5 refused surgery. Among the 8 patients who underwent surgery, 1 (12.5%) achieved pCR, and all achieved R0 resection. Tumor regression grades (TRG) observed were TRG0 in 1 (12.5%), TRG2 in 5 (62.5%), and TRG3 in 2 (25.0%) patients. Of the 13 evaluable patients, 8 (62%) achieved partial response (PR) and 5 (38%) had stable disease (SD). ORR and DCR were 62% (8/13) and 100.0% (13/13), respectively. Treatment-related adverse events (TRAEs) occurred in 100% of patients, but no grade 3-5 TRAEs were observed. Toxicity and post-surgery complications were limited, and surgical feasibility was not impacted.
Conclusions
Neoadjuvant adebrelimab combined with chemotherapy, followed by surgery and adjuvant treatment, demonstrated good efficacy and safety in patients with resectable locally advanced AEG, offering a promising treatment option for this patient population.
Clinical trial identification
NCT06198465.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
134P - Intracranial (IC) progression-free survival (PFS) with ivonescimab (Ivo) compared to placebo in the HARMONi-A trial of patients (Pts) with previously treated EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC)
Presenter: Li Zhang
Session: Poster Display session
Resources:
Abstract
135P - Efficacy and safety of tislelizumab combined with bronchial arterial infusion (BAI) chemotherapy in potentially resectable stage IIIB non-small cell lung cancer(NSCLC): A prospective, single-arm phase II clinical study
Presenter: Xu Ma
Session: Poster Display session
Resources:
Abstract
136P - Tislelizumab (TIS) plus chemotherapy (chemo) with or without bevacizumab (beva) for patients with EGFR-mutated nonsquamous NSCLC (nsq-NSCLC) after progression on EGFR tyrosine kinase inhibitor (TKI) therapy: An updated analysis
Presenter: Baohui Han
Session: Poster Display session
Resources:
Abstract
137P - Hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab for unresectable hepatocellular carcinoma: A single-arm, phase II study
Presenter: Jianbing Wu
Session: Poster Display session
Resources:
Abstract
138P - Interim results of neoadjuvant TACE plus lenvatinib and tislelizumab in resectable HCC at CNLC stages IB and IIA with high-risk of recurrence: A prospective, single-arm, phase II trial
Presenter: Yuhua Zhang
Session: Poster Display session
Resources:
Abstract
139P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display session
Resources:
Abstract
140P - Tislelizumab combined with lenvatinib and transarterial chemoembolization(TACE) neoadjuvant treatment in resectable CNLC IIa-IIb hepatocellular carcinoma: A prospective, single-arm, phase II study
Presenter: Zhibo Zhang
Session: Poster Display session
Resources:
Abstract
141P - Efficacy and safety of tislelizumab(T) combined with gemcitabine and cisplatin(GC) for patients with localized muscle-invasive bladder cancer(MIBC) after radical local surgery: A prospective, phase II study
Presenter: Ming Cao
Session: Poster Display session
Resources:
Abstract
143P - Strength of patient (pt) preference for atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) for the treatment of NSCLC: exploratory analyses from the IMscin002 study
Presenter: Margarita Majem Tarruella
Session: Poster Display session
Resources:
Abstract
144P - First-line cemiplimab monotherapy for advanced non-small cell lung cancer (NSCLC) of squamous histology: Subgroup analysis with 5-year results from EMPOWER-Lung 1
Presenter: Tamta Makharadze
Session: Poster Display session
Resources:
Abstract